Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29. doi: 10.3322/caac.21254 SiegelRL MillerKD JemalA Cancer statistics, 2015 CA Cancer J Clin 2015 65 5 29 10.3322/caac.21254 Open DOISearch in Google Scholar

2. Xu Y, Hu Y, Xu T, Yan K, Zhang T, Li Q, et al. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell Rep 2021; 37: 109854. doi: 10.1016/j.celrep.2021.109854 XuY HuY XuT YanK ZhangT LiQ RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage Cell Rep 2021 37 109854 10.1016/j.celrep.2021.109854 Open DOISearch in Google Scholar

3. Kumar V, Yadavilli S, Kannan R. A review on RNAi therapy for NSCLC: opportunities and challenges. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021; 13: e1677. doi: 10.1002/wnan.1677 KumarV YadavilliS KannanR A review on RNAi therapy for NSCLC: opportunities and challenges Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021 13 e1677 10.1002/wnan.1677 Open DOISearch in Google Scholar

4. Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezianska-Lasota E. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 2021; 22: 8856. doi: 10.3390/ijms22168885 KryczkaJ KryczkaJ Czarnecka-ChrebelskaKH Brzezianska-LasotaE Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy Int J Mol Sci 2021 22 8856 10.3390/ijms22168885 Open DOISearch in Google Scholar

5. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021; 27: 1345–56. doi: 10.1038/s41591-021-01450-2 WangM HerbstRS BoshoffC Toward personalized treatment approaches for non-small-cell lung cancer Nat Med 2021 27 1345 56 10.1038/s41591-021-01450-2 Open DOISearch in Google Scholar

6. Saha SK, Islam SMR, Kwak KS, Rahman MS, Cho SG. PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis. Cancer Gene Ther 2020; 27: 147–67. doi: 10.1038/s41417-019-0109-7 SahaSK IslamSMR KwakKS RahmanMS ChoSG PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis Cancer Gene Ther 2020 27 147 67 10.1038/s41417-019-0109-7 Open DOISearch in Google Scholar

7. Luo W, Wang J, Xu W, Ma C, Wan F, Huang Y, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. Cell Death Dis 2021; 12: 1043. doi: 10.1038/s41419-021-04296-1 LuoW WangJ XuW MaC WanF HuangY LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer Cell Death Dis 2021 12 1043 10.1038/s41419-021-04296-1 Open DOISearch in Google Scholar

8. Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell 2019; 51: 575–86.e574. doi: 10.1016/j.devcel.2019.10.007 BrownCW AmanteJJ ChhoyP ElaimyAL LiuH ZhuLJ Prominin2 drives ferroptosis resistance by stimulating iron export Dev Cell 2019 51 575 86.e574 10.1016/j.devcel.2019.10.007 Open DOISearch in Google Scholar

9. Brown CW, Chhoy P, Mukhopadhyay D, Karner ER, Mercurio AM. Targeting prominin2 transcription to overcome ferroptosis resistance in cancer. EMBO Mol Med 2021; 13: e13792. doi: 10.15252/emmm.202013792 BrownCW ChhoyP MukhopadhyayD KarnerER MercurioAM Targeting prominin2 transcription to overcome ferroptosis resistance in cancer EMBO Mol Med 2021 13 e13792 10.15252/emmm.202013792 Open DOISearch in Google Scholar

10. Li W, Zhu Y, Zhang K, Yu X, Lin H, Wu W, et al. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. Exp Mol Med 2020; 52: 409–22. doi: 10.1038/s12276-020-0390-4 LiW ZhuY ZhangK YuX LinH WuW PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer Exp Mol Med 2020 52 409 22 10.1038/s12276-020-0390-4 Open DOISearch in Google Scholar

11. Song SH, Kim TY. CTCF, cohesin, and chromatin in human cancer. Genomics Inform 2017; 15: 114–122. doi: 10.5808/GI.2017.15.4.114 SongSH KimTY CTCF, cohesin, and chromatin in human cancer Genomics Inform 2017 15 114 122 10.5808/GI.2017.15.4.114 Open DOISearch in Google Scholar

12. Guo Y, Perez AA, Hazelett DJ, Coetzee GA, Rhie SK, Farnham PJ. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops. Genome Biol 2018; 19: 160. doi: 10.1186/s13059-018-1531-0 GuoY PerezAA HazelettDJ CoetzeeGA RhieSK FarnhamPJ CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops Genome Biol 2018 19 160 10.1186/s13059-018-1531-0 Open DOISearch in Google Scholar

13. Zhang B, Zhang Y, Zou X, Chan AW, Zhang R, Lee TK, et al. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. J Pathol 2017; 243: 418–30. doi: 10.1002/path.4976 ZhangB ZhangY ZouX ChanAW ZhangR LeeTK The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma J Pathol 2017 243 418 30 10.1002/path.4976 Open DOISearch in Google Scholar

14. Lai Q, Li Q, He C, Fang Y, Lin S, Cai J, et al. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. Aging 2020; 12: 16270–93. doi: 10.18632/aging.103648 LaiQ LiQ HeC FangY LinS CaiJ CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis Aging 2020 12 16270 93 10.18632/aging.103648 Open DOISearch in Google Scholar

15. Sun Q, Zhang SY, Zhao JF, Han XG, Wang HB, Sun ML. HIF-1alpha or HOTTIP/CTCF promotes head and neck squamous cell carcinoma Progression and drug resistance by targeting HOXA9. Mol Ther Nucleic Acids 2020; 20: 164–75. doi: 10.1016/j.omtn.2019.12.045 SunQ ZhangSY ZhaoJF HanXG WangHB SunML HIF-1alpha or HOTTIP/CTCF promotes head and neck squamous cell carcinoma Progression and drug resistance by targeting HOXA9 Mol Ther Nucleic Acids 2020 20 164 75 10.1016/j.omtn.2019.12.045 Open DOISearch in Google Scholar

16. Li H, Lin PH, Gupta P, Li X, Zhao SL, Zhou X, et al. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Mol Cancer 2021; 20: 118. doi: 10.1186/s12943-021-01418-3 LiH LinPH GuptaP LiX ZhaoSL ZhouX MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer Mol Cancer 2021 20 118 10.1186/s12943-021-01418-3 Open DOISearch in Google Scholar

17. Wang S, Wang L, Hu H, Dong P. MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9. Allergol Immunopathol 2021; 49: 80–8. doi: 10.15586/aei.v49i6.451 WangS WangL HuH DongP MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9 Allergol Immunopathol 2021 49 80 8 10.15586/aei.v49i6.451 Open DOISearch in Google Scholar

18. He Y, Li Q, Zhou W, Gu Y, Jiang Y. Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia. Allergol Immunopathol 2021; 49: 72–7. doi: 10.15586/aei.v49i5.464 HeY LiQ ZhouW GuY JiangY Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia Allergol Immunopathol 2021 49 72 7 10.15586/aei.v49i5.464 Open DOISearch in Google Scholar

19. Yang Y, Yang X, Wu Y, Fu M. METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2. Allergol Immunopathol 2021; 49: 49–56. doi: 10.15586/aei.v49i5.445 YangY YangX WuY FuM METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2 Allergol Immunopathol 2021 49 49 56 10.15586/aei.v49i5.445 Open DOISearch in Google Scholar

20. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492 BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.21492 Open DOISearch in Google Scholar

21. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. doi: 10.3322/caac.21387 SiegelRL MillerKD JemalA Cancer Statistics, 2017 CA Cancer J Clin 2017 67 7 30 10.3322/caac.21387 Open DOISearch in Google Scholar

22. Nguyen TT, Gapihan G, Tetu P, Pamoukdjian F, El Bouchtaoui M, Leboeuf C, et al. Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes. Clin Transl Med 2020; 10: e198. doi: 10.1002/ctm2.198 NguyenTT GapihanG TetuP PamoukdjianF El BouchtaouiM LeboeufC Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes Clin Transl Med 2020 10 e198 10.1002/ctm2.198 Open DOISearch in Google Scholar

23. Liu W, Wang H, Bai F, Ding L, Huang Y, Lu C, et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-kappaB. Cell Prolif 2020; 53: e12776. doi: 10.1111/cpr.12776 LiuW WangH BaiF DingL HuangY LuC IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-kappaB Cell Prolif 2020 53 e12776 10.1111/cpr.12776 Open DOISearch in Google Scholar

24. Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol 2022; 40: 546–555. doi: 10.1200/JCO.21.01589 ChaftJE ShyrY SepesiB FordePM Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer J Clin Oncol 2022 40 546 555 10.1200/JCO.21.01589 Open DOISearch in Google Scholar

25. Taheri M, Shoorei H, Tondro Anamag F, Ghafouri-Fard S, Dinger ME. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. Exp Mol Pathol 2021; 123: 104602. doi: 10.1016/j.yexmp.2021.104602 TaheriM ShooreiH Tondro AnamagF Ghafouri-FardS DingerME LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin Exp Mol Pathol 2021 123 104602 10.1016/j.yexmp.2021.104602 Open DOISearch in Google Scholar

26. Chen TY, Zhou J, Li PC, Tang CH, Xu K, Li T, et al. SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling. Med Oncol 2022; 39: 36. doi: 10.1007/s12032-021-01626-3 ChenTY ZhouJ LiPC TangCH XuK LiT SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling Med Oncol 2022 39 36 10.1007/s12032-021-01626-3 Open DOISearch in Google Scholar

27. Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer 2020; 19: 134. doi: 10.1186/s12943-020-01256-9 WangW ZhaoM CuiL RenY ZhangJ ChenJ Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer Mol Cancer 2020 19 134 10.1186/s12943-020-01256-9 Open DOISearch in Google Scholar

28. Fang C, Wang Z, Han C, Safgren SL, Helmin KA, Adelman ER, et al. Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol 2020; 21: 247. doi: 10.1186/s13059-020-02152-7 FangC WangZ HanC SafgrenSL HelminKA AdelmanER Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation Genome Biol 2020 21 247 10.1186/s13059-020-02152-7 Open DOISearch in Google Scholar

29. Wang L, Peng Q, Yin N, Xie Y, Xu J, Chen A, et al. Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation. Mol Ther Nucleic Acids 2021; 26: 269–279. doi: 10.1016/j.omtn.2021.07.019 WangL PengQ YinN XieY XuJ ChenA Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation Mol Ther Nucleic Acids 2021 26 269 279 10.1016/j.omtn.2021.07.019 Open DOISearch in Google Scholar

30. Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, Fei Y, Wang L, Liang ZQ. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin 2016; 37: 1606–1622. doi: 10.1038/aps.2016.93 HanML ZhaoYF TanCH XiongYJ WangWJ WuF FeiY WangL LiangZQ Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells Acta Pharmacol Sin 2016 37 1606 1622 10.1038/aps.2016.93 Open DOISearch in Google Scholar